CSNK1D

CSNK1D (CKIdelta) is a serine/threonine kinase that functions as a core component of the mammalian circadian clock by phosphorylating PERIOD proteins to control their stability and subcellular distribution (PMID:15800623, PMID:11865049). It phosphorylates mPer1 and mPer3 to drive their ubiquitin-proteasome-dependent degradation and nuclear translocation, while having no effect on CRY-mediated transcriptional inhibition (PMID:11865049); a period-shortening T44A mutation that reduces kinase activity recapitulates a human familial advanced sleep phase phenotype in transgenic animals, establishing its central clock role (PMID:15800623). CKIdelta acts redundantly with CKIepsilon, since loss of both kinases—or competitive disruption of the PER2–kinase interaction—abolishes rhythms and depletes PER, revealing a non-catalytic PER-stabilizing function in addition to its catalytic one (PMID:19948962). Beyond the clock, CSNK1D has been implicated in several oncogenic axes: it phosphorylates and stabilizes HNRNPA2B1 to promote m6A-dependent maturation of miR-25-3p/miR-93-5p driving prostate cancer progression (PMID:37208565), interacts with and stabilizes DVL3 to activate Wnt/β-catenin signaling in hepatocellular carcinoma (PMID:36460966), and binds the SHH–PTCH1 complex to control the GLI1–BCL2 Hedgehog axis in head and neck squamous cell carcinoma (PMID:41353440). Earlier work also linked CKIdelta kinase activity to lymphocyte mitogenic responses and p53 status (PMID:12924632).

1. 1996 Medium

   Establishing the human gene sequence and locus was the prerequisite for studying CKIdelta in human biology and disease.

   Evidence cDNA sequencing and FISH/PCR chromosomal mapping of human CSNK1D

   PMID:8786104

   Open questions at the time

   • No functional or substrate information beyond sequence homology
   • Does not address tissue-specific expression or activity
2. 2002 High

   Identifying PER proteins as CKIdelta substrates answered how the kinase couples to clock output by linking phosphorylation to PER degradation and nuclear translocation.

   Evidence Cell-based phosphorylation/degradation assays, proteasome inhibition, and site-directed mutagenesis of mPer3 phosphosites

   PMID:11865049

   Open questions at the time

   • Did not determine in vivo physiological consequence of PER phosphorylation
   • Specific phosphosites driving each readout not fully mapped
3. 2003 Medium

   Linking CKIdelta activity to mitogenic stimulation, irradiation, and p53 status raised a role outside the clock in lymphocyte physiology and tumorigenesis.

   Evidence Kinase activity assays in lymphocytes/granulocytes and immunohistochemistry comparing p53+/+ and p53-/- mice

   PMID:12924632

   Open questions at the time

   • No direct substrate identified in this context
   • Mechanistic connection between CKIdelta activity and p53 unresolved
4. 2005 High

   A kinase-impairing mutation that shortens circadian period in vivo established CKIdelta as a causal clock component and a model for human sleep phase phenotypes.

   Evidence In vitro kinase assay of CKIdelta-T44A plus transgenic mouse and Drosophila models

   PMID:15800623

   Open questions at the time

   • Direct causative link to human FASPS is by phenotypic mimicry, not human genetics in this study
   • Structural basis of reduced activity not defined
5. 2009 High

   Genetic loss-of-function and binding-disruption experiments distinguished catalytic from non-catalytic roles, showing CKIdelta both phosphorylates and physically stabilizes PER and acts redundantly with CKIepsilon.

   Evidence CKIdelta-knockout MEFs, dominant-negative CKIepsilon, CKBD-P2 competitive binding, and bioluminescence rhythm assays

   PMID:19948962

   Open questions at the time

   • Molecular mechanism of the non-catalytic stabilizing role unresolved
   • Quantitative contribution of each kinase in different tissues unknown
6. 2014 Medium

   Demonstrating translational control of the Drosophila ortholog DBT by LARK/RBM4 showed that kinase abundance, not only activity, tunes clock period.

   Evidence Genetic epistasis, alternative-transcript translation assays, and behavioral period assays in Drosophila

   PMID:25211129

   Open questions at the time

   • Conservation of LARK/RBM4 translational regulation in mammalian CSNK1D not established
   • Single lab, ortholog-based
7. 2022 Medium

   Identifying a CSNK1D-DVL3 interaction connected the kinase to Wnt/β-catenin-driven hepatocellular carcinoma progression and drug resistance.

   Evidence Co-IP, siRNA/overexpression in HCC cells, xenograft growth, and β-catenin pathway western blots

   PMID:36460966

   Open questions at the time

   • Whether DVL3 stabilization requires CSNK1D catalytic activity not resolved
   • Single lab without reciprocal interaction validation across systems
8. 2023 Medium

   Showing CSNK1D phosphorylates and stabilizes HNRNPA2B1 linked the kinase to m6A-dependent miRNA maturation as an oncogenic mechanism in prostate cancer.

   Evidence Mass spectrometry interaction mapping, phosphorylation and m6A RNA-binding assays, plus xenograft experiments

   PMID:37208565

   Open questions at the time

   • Phosphosites on HNRNPA2B1 not defined
   • Generality beyond prostate cancer untested
9. 2025 Medium

   Identifying CSNK1D binding to the SHH-PTCH1 complex implicated it in Hedgehog/GLI1-BCL2 signaling in head and neck squamous cell carcinoma.

   Evidence Co-IP binding assays, siRNA/overexpression, pharmacological inhibition (SB-203580), and GLI1/BCL2 western blots

   PMID:41353440

   Open questions at the time

   • Whether complex regulation depends on kinase activity vs scaffolding unresolved
   • Single study; direct phosphorylation of complex components not shown

• How CSNK1D's circadian and oncogenic functions are mechanistically unified—and whether its catalytic versus non-catalytic activities are differentially deployed across these contexts—remains unresolved.
• No structural model linking substrate selectivity across pathways
• Regulation of CSNK1D activity in tumor contexts undefined
• Catalytic dependence of cancer interactions not established